local_hospital

PediaMed Wolfsburg

Address
Sauerbruchstrasse 7, Klieversberg, 38440 Wolfsburg, Germany

Pediatric Oncology and Leukemia

At PediaMed Wolfsburg, clinical research in hematologic diseases focuses on childhood and adolescent leukemia, especially acute lymphoblastic leukemia and related high-risk subtypes. These studies are designed to improve survival, refine treatment choices, and strengthen disease control in young patients.

  • Testing better treatment strategies for Philadelphia chromosome-positive acute lymphoblastic leukemia
  • Evaluating intensified and risk-adapted care for pediatric B-cell and T-cell leukemia
  • Improving long-term outcomes in children and adolescents with leukemia

The work here aims to make therapy more effective while balancing treatment burden for younger patients and their families.

Gastrointestinal and Digestive Cancers

Research in digestive system diseases is a major focus, with trials in colon cancer, rectal cancer, gastric cancer, and gastroesophageal junction adenocarcinoma. These studies explore new ways to improve surgery-related outcomes, reduce recurrence, and extend survival in both early and advanced disease.

  • Assessing treatments for colon cancer and rectal cancer to improve disease-free survival
  • Studying new combination approaches in gastric and gastroesophageal cancers
  • Supporting organ-preserving strategies and better preoperative care in resectable digestive cancers

The site investigates both localized and metastatic disease, with the goal of improving treatment effectiveness across the full spectrum of gastrointestinal oncology.

Immune-Mediated and Skin Disorders

Clinical trials at this site also address immune system diseases and skin and connective tissue diseases, including atopic dermatitis and ulcerative colitis. The research is centered on easing symptoms, preventing disease flares, and improving everyday quality of life.

  • Preventing atopic dermatitis in children at high risk of developing the condition
  • Evaluating new treatment options for moderately to severely active ulcerative colitis
  • Exploring better control of inflammatory and allergic diseases

These studies reflect a broad interest in immune-related conditions, from early prevention in children to treatment of chronic inflammatory disease in adults.

Women’s Health, Hormonal Conditions, and Oncology Supportive Care

Research in female urogenital diseases and pregnancy complications and hormonal diseases includes trials for ovarian cancer and vasomotor symptoms linked to cancer therapy. The aim is to improve symptom relief, support treatment tolerance, and enhance outcomes for women undergoing cancer care.

  • Studying treatment approaches for epithelial ovarian cancer
  • Evaluating relief of moderate to severe hot flashes in women receiving endocrine therapy
  • Improving supportive care for women living with hormone-related treatment side effects

These trials combine cancer treatment research with efforts to make ongoing therapy more manageable for patients.

Lymphomas and Blood Cancers

The site’s hemic and lymphatic diseases portfolio includes studies in aggressive B-cell lymphomas and other blood cancers. Research is focused on finding more effective combinations for older adults and improving disease control in hard-to-treat lymphoma subtypes.

  • Testing new treatment combinations for diffuse large B-cell lymphoma
  • Exploring better options for older patients with untreated lymphoma
  • Advancing care for complex and high-risk hematologic malignancies

These studies aim to expand treatment possibilities while keeping therapy suitable for patients who may not tolerate intensive regimens.

Site Profile and Cross-Disciplinary Clinical Research

PediaMed Wolfsburg in Wolfsburg, Germany supports a diverse trial portfolio across pediatric oncology, gastrointestinal cancer, inflammatory disease, and supportive care. With multiple investigators involved, the site contributes to research that seeks better survival, improved symptom control, and more patient-friendly treatment strategies.

  • Broad research across oncology, immunology, and digestive diseases
  • Focus on new therapies, treatment effectiveness, and organ-preserving approaches
  • Clinical studies spanning children, adults, and older patients

The overall research landscape combines disease-specific innovation with practical goals that matter to patients, such as better outcomes, fewer complications, and improved quality of life.

Site Overview

assignment
26
connected trials
corporate_fare
17
sponsors
science
64
IMPs

Activity Indicator

Last 6 months

1
Trials started
-75% vs previous period.
4
Trials started 6–12 months ago
26
Total trials linked
Highly Active
trending_downDeclining-75%
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 3 of 7 therapeutic areas and 15 of 64 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 64 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
10
Sponsors (total)
17
Active sponsors
9

Sponsor Network

Top 9 by active trials.

lock +8 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 2 161 other sites in Germany

description
Trial volume
26
Outperforms 92% of sites
public
Therapeutic diversity
7areas
Outperforms 93% of sites
groups
Sponsor diversity
17sponsors
Outperforms 92% of sites

Therapeutic Area Benchmark — Germany

Select a therapeutic area to compare against other sites in Germany.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Germany

Market Share

Country: Germany

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in PediaMed Wolfsburg

lock Showing 1 of 26 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED/GLA 2022-1)University Of SaarlandPhase IIIRecruitingApr 2023

IMP list

lock Showing 1 of 64 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Fluorouracil12Unknown2016-11-072025-12-16

Request feasibility information

Ask this centre about capacity, equipment and patient population.

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.